Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03046316

Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy

Local Consolidative Therapy (LCT) in Patients With Advanced Stage Non-small Cell Lung Cancer Who do Not Progress After Front Line Systemic Therapy

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Guangdong Association of Clinical Trials · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a prospective single arme real-world study clinical study, which aims to investigate the overall benefit and safety of consolidative therapy in advanced NSCLC (stage III/IV) patients , who do not progress after front line systemic therapy (chemotherapy, target therapy or immunological checkpoint inhibitors).

Detailed description

It is required that pathological diagnosis and genetic profile including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) be established prior to enrollment. Standard front line systemic should be given according to clinical practice. Molecular targeting drugs for patients with driving mutations should be acquired legally. Patients without driving mutations should undergo standard first line chemotherapy and or immunological checkpoint inhibitors. One cycle is three weeks and response evaluation is done every two cycles. CR, PR and SD should be confirmed after four cycles of therapy. Patients, who achieve non-PD after four cycles of treatment, with distant metastasis involving no more than five total metastatic lesions, will be screened and enrolled.

Conditions

Interventions

TypeNameDescription
OTHERlocal consolidative treatmentlocal consolidative treatment to primary or metastases, which includes surgery, radiotherapy or interventional therapy

Timeline

Start date
2020-06-01
Primary completion
2022-07-01
Completion
2026-07-01
First posted
2017-02-08
Last updated
2020-07-23

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03046316. Inclusion in this directory is not an endorsement.